Memgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2004-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.memgenbio.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced CancerNon Small Cell Lung CancerMelanomaCutaneous Squamous Cell CarcinomaMetastatic CancerPancreatic CancerSolid TumorTriple Negative Breast CancerMerkel Cell CarcinomaHead and Neck Cancer
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Memgen, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05076760
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Duke Cancer Institute, Durham, North Carolina, United States
News
No news found